{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:00:05Z","timestamp":1779375605654,"version":"3.53.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.ijantimicag.2011.09.004","type":"journal-article","created":{"date-parts":[[2011,10,22]],"date-time":"2011-10-22T05:05:01Z","timestamp":1319259901000},"page":"3-10","source":"Crossref","is-referenced-by-count":28,"special_numbering":"S","title":["Antimicrobials in urogenital infections"],"prefix":"10.1016","volume":"38","author":[{"given":"Florian M.E.","family":"Wagenlehner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Wullt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Perletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-135-1-200107030-00012","article-title":"Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections","volume":"135","author":"Gupta","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0891-5520(03)00004-7","article-title":"The current management strategies for community-acquired urinary tract infection","volume":"17","author":"Hooton","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/dkg028","article-title":"An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project","volume":"51","author":"Kahlmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0025","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/520427","article-title":"Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women, Infectious Diseases Society of America (IDSA)","volume":"29","author":"Warren","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0030","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprimsulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0480","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0040","doi-asserted-by":"crossref","first-page":"14221","DOI":"10.1073\/pnas.0504314102","article-title":"Structure and reactivity of hydroxypropylphosphonic acid epoxidase in fosfomycin biosynthesis by a cation- and flavin-dependent mechanism","volume":"102","author":"McLuskey","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0045","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2011.09.004_bib0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0924-8579(03)00231-0","article-title":"Why fosfomycin trometamol as first line therapy for uncomplicated UTI?","volume":"22","author":"Schito","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1179\/joc.2002.14.3.237","article-title":"In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol","volume":"14","author":"Ungheri","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0060","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","article-title":"Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy","volume":"54","author":"Naber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF01643751","article-title":"Influence of fosfomycin on the intestinal and pharyngeal flora of man","volume":"19","author":"Knothe","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0070","first-page":"220","article-title":"Antimicrobial therapy with nitroheterocyclic compounds, for example, metronidazole and nitrofurantoin","volume":"16","author":"Hof","year":"1988","journal-title":"Immun Infekt"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000401065","article-title":"The pharmacokinetics of nitrofurantoin and its related bioavailability","volume":"25","author":"Conklin","year":"1978","journal-title":"Antibiot Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0080","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1464-410X.2008.07809.x","article-title":"Nitrofurantoin: the return of an old friend in the wake of growing resistance","volume":"102","author":"Kashanian","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1155\/2001\/601743","article-title":"Susceptibility of community Gram-negative urinary tract isolates to mecillinam and other oral agents","volume":"12","author":"Mazzulli","year":"2001","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0090","first-page":"CD001534","article-title":"Long-term antibiotics for preventing recurrent urinary tract infection in children","volume":"3","author":"Williams","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1665-2681(19)31944-1","article-title":"Nitrofurantoininduced lung- and hepatotoxicity","volume":"6","author":"Koulaouzidis","year":"2007","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1179\/joc.1997.9.3.203","article-title":"Effect of norfloxacin, trimethoprimsulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections","volume":"9","author":"Mavromanolakis","year":"1997","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0105","first-page":"73","article-title":"Effect of beta-lactam prodrugs on human intestinal microflora","volume":"49","author":"Sjovall","year":"1986","journal-title":"Scand J Infect Dis Suppl"},{"issue":"Suppl. B","key":"10.1016\/j.ijantimicag.2011.09.004_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/3.suppl_B.13","article-title":"The mechanism of action of mecillinam","volume":"3","author":"Spratt","year":"1977","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2011.09.004_bib0115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0924-8579(03)00235-8","article-title":"Pivmecillinam \u2013 therapy of choice for lower urinary tract infection","volume":"22","author":"Graninger","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1179\/joc.2001.13.3.299","article-title":"Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora","volume":"13","author":"Sullivan","year":"2001","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0732-8893(98)00158-8","article-title":"Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997","volume":"35","author":"Jones","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0130","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0732-8893(02)00467-4","volume":"45","author":"Gordon","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0135","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0732-8893(01)00254-1","article-title":"Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America)","volume":"40","author":"Mathai","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1046\/j.1198-743x.2001.00326.x","article-title":"A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections","volume":"7","author":"Bouza","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0924-8579(02)00100-0","article-title":"Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994\u20132000","volume":"19","author":"Wagenlehner","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0150","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.eururo.2006.08.012","article-title":"Prevalence of hospital-acquired urinary tract infections in urology departments","volume":"51","author":"Bjerklund Johansen","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0155","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198802183180706","article-title":"Beta-lactam antibiotics (1)","volume":"318","author":"Donowitz","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0160","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2165\/00003495-199345060-00002","article-title":"Penicillins. A current review of their clinical pharmacology and therapeutic use","volume":"45","author":"Nathwani","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0485","first-page":"2","article-title":"Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific and South East Asian Regions, 2009","volume":"35","author":"Tapsall","year":"2011","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0170","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1473-3099(01)00066-4","article-title":"Effect of antimicrobial agents on the ecological balance of human microflora","volume":"1","author":"Sullivan","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0175","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4065\/74.2.187","article-title":"The cephalosporins","volume":"74","author":"Marshall","year":"1999","journal-title":"Mayo Clin Proc"},{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2011.09.004_bib0185","first-page":"9","article-title":"The antimicrobial activity of cephalexin against old and new pathogens","volume":"59","author":"Jones","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0190","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0022-5347(17)51709-7","article-title":"Longterm prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidone-iodine","volume":"130","author":"Brumfitt","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0195","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2165\/00003088-198917030-00003","article-title":"Clinical pharmacokinetics of cefotiam","volume":"17","author":"Brogard","year":"1989","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2165\/00003495-199652010-00009","article-title":"Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy","volume":"52","author":"Perry","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0205","first-page":"937","article-title":"Cephalosporins: rationale for clinical use","volume":"43","author":"Molavi","year":"1991","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0210","first-page":"114","article-title":"Cefotaxime: microbiology, pharmacology, and clinical use","volume":"1","author":"Dudley","year":"1982","journal-title":"Clin Pharm"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2165\/00003495-198835060-00002","article-title":"Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration","volume":"35","author":"Brogden","year":"1988","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0220","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/106002809302701111","article-title":"Cefpodoxime proxetil: a new, broadspectrum, oral cephalosporin","volume":"27","author":"Chocas","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0225","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/j.1875-9114.1997.tb03746.x","article-title":"Ceftibuten: an overview","volume":"17","author":"Owens","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0230","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00045391-199406000-00008","article-title":"Multiple-dose pharmacokinetics of ceftibuten in healthy adults and geriatric volunteers","volume":"1","author":"Radwanski","year":"1994","journal-title":"Am J Ther"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0235","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02725589","article-title":"Cefpodoxime: pharmacokinetics and therapeutic uses","volume":"70","author":"Chugh","year":"2003","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0240","first-page":"1878","article-title":"Structure\u2013activity relationship of ceftazidime. Consequences on the bacterial spectrum","volume":"17","author":"Bergogne-Berezin","year":"1988","journal-title":"Presse Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0245","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1177\/106002809603001211","article-title":"Cefepime: a fourth-generation parenteral cephalosporin","volume":"30","author":"Wynd","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-200847010-00003","article-title":"Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity","volume":"47","author":"Murthy","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0255","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568012023355018","article-title":"Current status of oral carbapenem development","volume":"1","author":"Kumagai","year":"2002","journal-title":"Curr Med Chem Anti-Infect Agents"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2011.09.004_bib0265","doi-asserted-by":"crossref","first-page":"ii7","DOI":"10.1093\/jac\/dkh203","article-title":"Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties","volume":"53","author":"Hammond","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0270","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0275","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4065\/74.4.420","article-title":"Carbapenems and monobactams: imipenem, meropenem, and aztreonam","volume":"74","author":"Hellinger","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diagmicrobio.2004.12.008","article-title":"Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various betalactamase resistance mechanisms","volume":"52","author":"Jones","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0285","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1128\/AAC.43.4.727","article-title":"Aminoglycosides: activity and resistance","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0290","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/AAC.4.4.402","article-title":"Structure\u2013activity relationships among the aminoglycoside antibiotics: role of hydroxyl and amino groups","volume":"4","author":"Benveniste","year":"1973","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0295","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/clpt.1989.4","article-title":"Once-daily dosing decreases renal accumulation of gentamicin and netilmicin","volume":"45","author":"Verpooten","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0305","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0378-5955(98)00200-7","article-title":"Stimulation of free radical formation by aminoglycoside antibiotics","volume":"128","author":"Sha","year":"1999","journal-title":"Hear Res"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0310","first-page":"3","article-title":"Prevention and modulation of aminoglycoside ototoxicity","volume":"1","author":"Perletti","year":"2008","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0924-8579(98)00059-4","article-title":"Classification of fluoroquinolones","volume":"10","author":"Naber","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0320","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0325","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","article-title":"Quinolones in 2005: an update","volume":"11","author":"Van Bambeke","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0378-5173(91)90121-4","article-title":"Pharmacokinetic interactions of norfloxacin with some metallic medicinal agents","volume":"68","author":"Okhamafe","year":"1991","journal-title":"Int J Pharma"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0335","doi-asserted-by":"crossref","first-page":"56S","DOI":"10.1016\/S0002-9343(20)31140-2","article-title":"Pharmacokinetics of gyrase inhibitors, part 2: renal and hepatic elimination pathways and drug interactions","volume":"94","author":"Sorgel","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0924-8579(00)00362-9","article-title":"Which fluoroquinolones are suitable for the treatment of urinary tract infections?","volume":"17","author":"Naber","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl.","key":"10.1016\/j.ijantimicag.2011.09.004_bib0345","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/infdis\/128.Supplement_3.S686","article-title":"The concentration of trimethoprim in prostatic fluid: nonionic diffusion or active transport?","volume":"128","author":"Stamey","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-5347(17)61919-0","article-title":"Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid","volume":"103","author":"Stamey","year":"1970","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijantimicag.2007.08.025","article-title":"Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400mg to healthy volunteers","volume":"31","author":"Wagenlehner","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0360","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1128\/AAC.43.9.2311","article-title":"Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based method","volume":"43","author":"Cross","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0365","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/74.7.730","article-title":"Trimethoprimsulfamethoxazole","volume":"74","author":"Smilack","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0370","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"An international survey on etiology and susceptibility of uropathogens isolated from women with uncomplicated UTI: the ARESC study","author":"Naber","year":"2007"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2011.09.004_bib0375","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0924-8579(03)00229-2","article-title":"Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study","volume":"22","author":"Kahlmeter","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0380","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/AAC.46.8.2540-2545.2002","article-title":"Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States","volume":"46","author":"Karlowsky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0385","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0924-8579(01)00466-6","article-title":"Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States, Tracking Resistance in the United States Today. The Surveillance Network","volume":"19","author":"Karlowsky","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0390","first-page":"244","article-title":"Co-trimoxazole concentration in the prostatic fluid of patients with subacute and chronic prostatitis","volume":"102","author":"Hofstetter","year":"1984","journal-title":"Fortschr Med"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0395","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/clinids\/4.2.475","article-title":"Prostatitis: review of pharmacokinetics and therapy","volume":"4","author":"Meares","year":"1982","journal-title":"Rev Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2011.09.004_bib0400","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","article-title":"Gatifloxacin 200mg or 400mg once daily is as effective as ciprofloxacin 500mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections","volume":"23","author":"Naber","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0405","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1159\/000049840","article-title":"EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU)","volume":"40","author":"Naber","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0410","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0025-6196(12)65046-0","article-title":"Vancomycin","volume":"62","author":"Hermans","year":"1987","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0415","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin","volume":"37","author":"Wood","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0420","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of the oxazolidinone antibacterial agents","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0425","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2011.09.004_bib0430","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0435","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0440","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.27.5.771","article-title":"Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism","volume":"27","author":"Carson","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0445","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.diagmicrobio.2008.08.009","article-title":"Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey","volume":"62","author":"Beekmann","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0450","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/00365540110076714","article-title":"Ecological effects of linezolid versus amoxicillin\/clavulanic acid on the normal intestinal microflora","volume":"33","author":"Lode","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0455","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.31.7.1093","article-title":"Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032","volume":"31","author":"Allen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0460","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.44.12.3447-3450.2000","article-title":"Comparative In vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens","volume":"44","author":"Snydman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0465","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.idc.0000144898.12957.eb","article-title":"Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to Gram-positive bacteria","volume":"12","author":"Naber","year":"2004","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0470","first-page":"160","article-title":"Chronic prostatitis\/chronic pelvic pain syndrome: finding a way forward in the United Kingdom: report from the first United Kingdom symposium on chronic prostatitis, January 30, 2008, London, United Kingdom","volume":"10","author":"Nickel","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.ijantimicag.2011.09.004_bib0475","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911003633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857911003633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:50:22Z","timestamp":1713055822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857911003633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":95,"alternative-id":["S0924857911003633"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.09.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}